Diffuse sclerosing variant of papillary thyroid carcinoma (DSPC) is a rare variant of papillary thyroid carcinoma (PTC). We report a 61-year-old female of DSPC whose course was complicated by multiple metastases and an elevated serum carcinoembryonic antigen (CEA) level.
Summary:
The patient presented with upper back pain. X-ray showed an osteolytic lesion of the sixth cervical spinous process. She had a hard, nonmovable mass with fixed enlarged lymph nodes (LNs) over right neck. Fine-needle aspiration cytology revealed PTC with LNs metastasis. Positron emission tomography demonstrated multiple brain, bone, liver, and lung metastases. However, the patient had an elevated serum CEA level. She underwent a total thyroidectomy and 200 mCi radioactive 131I therapy. The pathological findings were diffuse sclerosing variant of PTC with capsular and lymph vessel invasion. A double staining of tumor specimen appeared concomitantly positive for CEA and thyroglobulin.
Conclusions:
To our knowledge, DSPC with an elevated CEA level is extremely rare.
CarcangiuML, BianchiS. 1989. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol, 13:1041–1049.
3.
SywakM, PasiekaJL, OgilvieT. 2004. A review of thyroid cancer with intermediate differentiation. J Surg Oncol, 86:44–54.
4.
RegalbutoC, MalandrinoP, TumminiaA, Le MoliR, VigneriR, PezzinoV. 2011. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases. Thyroid, 21:383–389.
5.
FujimotoY, ObaraT, ItoY, KodamaT, AibaM, YamaguchiK. 1990. Diffuse sclerosing variant of papillary carcinoma of the thyroid. Clinical importance, surgical treatment, and follow-up study. Cancer, 66:2306–2312.
6.
SchroderS, BayV, DumkeK, KremensB, Müller-GärtnerHW, BöckerW, KastendieckH. 1990. Diffuse sclerosing variant of papillary thyroid carcinoma. S-100 protein immunocytochemistry and prognosis. Virchows Arch A Pathol Anat Histopathol, 416:367–371.
7.
ChowSM, ChanJK, LawSC, TangDL, HoCM, CheungWY, WongIS, LauWH. 2003. Diffuse sclerosing variant of papillary thyroid carcinoma—clinical features and outcome. Eur J Surg Oncol, 29:446–449.
8.
LamAK, LoCY. 2006. Diffuse sclerosing variant of papillary carcinoma of the thyroid: a 35-year comparative study at a single institution. Ann Surg Oncol, 13:176–181.
9.
PatelSG, ShahJP. 2005. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J Clin, 55:242–258.
10.
FalvoL, GiacomelliL, D'AndreaV, MarzulloA, GuerrieroG, de AntoniE. 2006. Prognostic importance of sclerosing variant in papillary thyroid carcinoma. Am Surg, 72:438–444.
11.
FukushimaM, ItoY, HirokawaM, AkasuH, ShimizuK, MiyauchiA. 2009. Clinicopathologic characteristics and prognosis of diffuse sclerosing variant of papillary thyroid carcinoma in Japan: an 18-year experience at a single institution. World J Surg, 33:958–962.
12.
LeeJY, ShinJH, HanBK, KoEY, KangSS, KimJY, OhYL, ChungJH. 2007. Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. Thyroid, 17:567–573.
13.
KwakJY, KimEK, HongSW, OhKK, KimMJ, ParkCS, CheongWY. 2007. Diffuse sclerosing variant of papillary carcinoma of the thyroid: ultrasound features with histopathological correlation. Clin Radiol, 62:382–386.
14.
SheuSY, SchwertheimS, WormK, GrabellusF, SchmidKW. 2007. Diffuse sclerosing variant of papillary thyroid carcinoma: lack of BRAF mutation but occurrence of RET/PTC rearrangements. Mod Pathol, 20:779–787.
15.
KooJS, HongS, ParkCS. 2009. Diffuse sclerosing variant is a major subtype of papillary thyroid carcinoma in the young. Thyroid, 19:1225–1231.
16.
ThompsonLD, WienekeJA, HeffessCS. 2005. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol, 16:331–348.
17.
AgriantonisDJ, HallL, WilsonMA. 2009. Utility of SPECT/CT as an adjunct to planar whole body I-131 imaging: liver metastasis from papillary thyroid cancer. Clin Nucl Med, 34:247–248.
18.
DinneenSF, ValimakiMJ, BergstralhEJ, GoellnerJR, GormanCA, HayID. 1995. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab, 80:2041–2045.
19.
SchönbergerJ, RüschoffJ, GrimmD, MarienhagenJ, RümmeleP, MeyringerR, KossmehlP, HofstaedterF, EillesC. 2002. Glucose transporter 1 gene expression is related to thyroid neoplasms with an unfavorable prognosis: an immunohistochemical study. Thyroid, 12:747–754.
20.
WongTZ, JainMK, SprattSE. 2008. I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. Clin Nucl Med, 33:834–837.
21.
ScottGC, MeierDA, DickinsonCZ. 1995. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med, 36:1843–1845.
MachensA, UkkatJ, HauptmannS, DralleH. 2007. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg, 142:289–293.
24.
KobayashiK, YokozawaT, ItoY, MatsuzukaH, KumaK, MiyauchiA, KakudoK. 2003. A case with poorly differentiated follicular carcinoma of the thyroid produced and secreted CEA. Nippon Geka Gakkai Zasshi, 104:488–490.
25.
OstrowskiML, MerinoMJ. 1996. Tall cell variant of papillary thyroid carcinoma: a reassessment and immunohistochemical study with comparison to the usual type of papillary carcinoma of the thyroid. Am J Surg Pathol, 20:964–974.
26.
SpencerCA, BergoglioLM, KazarosyanM, FatemiS, LoPrestiJS. 2005. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab, 90:5566–5575.
